Board summary
Key figures
54,360
Registered population
67.3% aged 18–64
15.9%
Aged 65+
ICB 21.9% · England 17.9%
14.4%
Ethnic minority (non-White)
4.7% Asian · England 9.6%
7.8%
In IMD quintile 1
ICB 9.2% · England 21.0%
~3,732
Core20 residents (est.)
Resident basis; registered basis ~3,829 · see page 3
6,358
Hypertension register
+8.03% in 3 yrs · England +5.60%
588
SMI register
12.7% of Brighton and Hove (LAD)'s
682
COPD register
Reviews +1.06% in 3 yrs
Forecast to 2030
7,528
Hypertension patients, 2030
+1,170 on today
60.1%
QRISK ≥20% on statins, 2030
+1.66pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage trails England and fell.
Coverage is 56.0% versus 65.7% in England (fell 2.9% vs +4.4%), leaving about 1,400 of 3,259 registered patients unreviewed, which may reflect recall gaps.
High-risk lipid therapy trails England at higher cost.
Lipid therapy in CKD is 59.1% (England 70.3%) and QRISK ≥ 20% is 56.6% (63.6%), while item cost is £2.70 versus £1.86 in England.
Breast screening and older-adult control outpace benchmarks.
Breast screening is 81.7% (England 69.9%), while frail diabetes HbA1c control reaches 84.2% (England 81.9%) and 80+ BP control rose +4.7% (England +2.2%).
Population, age and ethnicity
Patients aged 18 to 64 comprise 67.3% alongside 8,645 older adults
Across 54,360 registered patients, 67.3% (36,572) are aged 18-64, compared with 71.4% in Brighton and Hove (LAD), 60.5% in NHS Sussex Integrated Care Board, and 62.7% in England. Patients aged 65 and over comprise 15.9% (8,645), compared with 14.0% in Brighton and Hove (LAD), 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Census usual residents in associated areas are 85.6% White (Brighton and Hove (LAD) 85.4%, NHS Sussex Integrated Care Board 91.0%, England 81.1%), leaving a 14.4% ethnic minority share.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Brighton and Hove LA) | 2,702 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.9% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA) | 1,485 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Brighton and Hove LA) | 19.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 7.8%, below national and borough levels
The Core20 cohort (IMD quintile 1) comprises 7.8% of registered patients at PCN level, below England (21.0%) by 13.3 percentage points, below Brighton and Hove (LAD) (17.6%) by 9.8 percentage points, and below NHS Sussex Integrated Care Board (9.2%) by 1.4 percentage points. Core20 reflects residence in the most deprived national areas and is not a local performance target.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
588
SMI register
1.03% recorded prevalence
289
Learning disability register
0.51% recorded prevalence
23
Care homes, 578 beds
In the PCN catchment
8.2%
Provide unpaid care
Brighton and Hove (LAD), Census 2021
Recorded prevalence is 1.0% for severe mental illness (588 patients; England 1.0%) and 0.5% for learning disability (289 patients; England 0.6%). The PCN catchment contains 23 care homes with 578 beds. Crude register prevalence does not establish unmet need or coding quality, and care home bed capacity does not establish occupancy or registered resident numbers.
Severe mental illness: physical health checks
SMI blood pressure checks reached 72.3% (England 83.4%; Brighton and Hove 77.2%), with Beaconsfield Medical Practice at 60.9%, while BMI recording was 72.6% (England 82.1%). Lagging published checks is consistent with physical health review gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,358
Hypertension register
+8.03%
Register growth, 3 yrs
Brighton and Hove (LAD) +7.27% · England +5.60%
+0.89pp
BP control, under 80
≤140/90 · +3.58pp aged 80+
+1,170
More patients by 2030
Forecast 7,528 (13.02%)
Hypertension case-finding and control
Recorded hypertension prevalence is 11.2% (6,358 patients), above Brighton and Hove (10.5%) but below NHS Sussex Integrated Care Board (16.3%) and England (15.2%), though the register grew +8.0% over 2023 to 2025 (England +5.6%). For patients under 80, blood pressure control to <= 140/90 mmHg is 65.8% (England 67.8%), while in patients aged 80 and over control reaches 79.1% (England 81.2%), rising +4.7% over 2023 to 2025 (England +2.2%). Crude prevalence may reflect a younger list (67.3% aged 18-64), and matching observation bases cannot be confirmed. Lower control rates in patients under 80 compared with England indicate an opportunity to expand structured blood pressure reviews across primary care.
Lipids and statins
Lipid-lowering therapy reaches 56.6% in patients with QRISK >= 20% (England 63.6%), 59.1% in CKD (England 70.3%), and 78.8% in diabetes with CVD (England 84.4%). Trailing national coverage across all three cohorts indicates an urgent opportunity to prioritise recall audits for high-risk patients needing lipid-lowering therapy.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 56,030 | £2.70 | £2.42 | £1.86 | £151,281 |
| Cardiovascular (all), 2025 | 80,642 | £3.32 | £3.32 | £3.33 | £267,731 |
In 2026, lipid-modifying drugs cost £2.70 per item across 56,030 items, compared with £1.86 in England and £2.42 in NHS Sussex Integrated Care Board, spending £47,065 more than at England's unit cost. Higher unit costs than England indicate an opportunity to review local formulary choices and prescribing spend across member practices, noting unit cost is not efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.94%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.51%
Asthma prevalence, PCN 3-yr % change
Asthma annual review coverage fell 2.9% over 2023 to 2025 (England +4.4%) to 56.0% (England 65.7%; Brighton and Hove 60.1%), leaving about 1,400 unreviewed of 3,259 registered patients. COPD reviews reached 68.0% (England 76.4%), with 682 patients on the register. Prescribing of asthma management items for ages 5-19 was 959 rate per 1,000 (England 1,488 rate). Trailing reviews may reflect unverified routine recall shortfalls.
Cancer register and children's immunisation
The cancer register records 2,100 patients (3.7% prevalence vs England 3.8%). In childhood immunisations, 6-in-1 coverage at 12 months is 88.0% (NHS Sussex ICB 92.9%; England 91.0%), falling 7 pp below the 95.0% target. At age 5, MMR dose 2 is 89.6%, trailing MMR dose 1 (94.8%) by 5.2 pp, which could reflect unverified recall delays before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB, 58.5% of cancers with a known stage were diagnosed at stage 1 or 2 in 2022 (4,799 of 8,209 staged cases), rising 5 pp since 2013 and above England (55.3%), but below the 75.0% national ambition by 16.5 pp (about 1,360 extra early-stage cases needed). Staged cancers were 64.3% of registrations (England 67.0%). Cancer register prevalence is 3.7% (2,100 patients), rising +13.4% over 2023 to 2025 (England +9.0%). Breast screening reached 81.7% (England 69.9%). Cervical screening is 68.6% (England 66.8%), but fell 2.3% over 2023 to 2025 (England -1.0%) and is 57.4% at Stanford Medical Centre.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, University Hospitals Sussex NHS Foundation Trust met the 62-day cancer standard for 65.2% of pathways, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), and below the 85.0% standard by 19.8 pp. Its 28-day faster diagnosis standard was 74.0% (England 79.3%; 75.0% standard). For 6+ week diagnostic waits, MRI was 5.6% and CT was 8.6% (England 21.4% and 9.9%). These figures reflect acute provider waiting times and do not measure PCN referral performance.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | Brighton and Hove residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 23,615 | 309,615 |
| Referrals | 5,590 | 66,930 |
| Patients with a contact | 7,350 | 85,660 |
Community services (residents of Brighton and Hove), Jun 2026 (provisional). In Jun 2026 (provisional), community health service contacts for Brighton and Hove residents totalled 23,615, of which 14,325 (60.7%) were with adults aged 65 and over. These figures describe activity across all borough residents rather than PCN-specific care, illustrating older-adult demand across community health services.
Practice variation and patient experience
Practice telephone access spans 51.8 pp and vaccination achievement spans 74.6 pp
In 2025/26, QOF clinical-domain achievement was 99.2% at Beaconsfield Medical Practice (England 97.1%). In the vaccination and immunisation domain, achievement spanned 74.6 pp, from 17.2% at Stanford Medical Centre (personalised care adjustment rate 7.4%) to 91.7% at Warmdene Surgery, compared with 55.2% across England.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| The Haven Practice | 115 | 0.0 | 91.4% | 82.9% | 90.9% |
| Warmdene Surgery | 127 | 0.0 | 76.8% | 81.1% | 90.2% |
| Beaconsfield | 99 | 1.2 | 59.4% | 70.4% | 86.8% |
| Stanford | 95 | 16.4 | 71.0% | 63.7% | 82.3% |
| Preston Park | 115 | 7.4 | 39.6% | 70.1% | 73.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked three-year trends trail England across clinical pathways
Over 2023 to 2025, 16 of 25 tracked three-year trends trailed England. Dementia register prevalence fell 2.2% (England +6.0%), stroke prevalence fell 4.2% (England +2.3%), and asthma annual reviews fell 2.9% (England +4.4%). Non-frail diabetes HbA1c control also fell 0.8% (England +4.4%). Conversely, three-year strengths outpaced national growth: blood pressure control in patients aged 80+ rose 4.7% (England +2.2%), statin treatment in diabetes without cardiovascular disease rose 4.2% (England +2.1%), and severe mental illness BMI recording rose 6.7 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Heart failure reviews
Asthma reviews
Stroke register
Diabetes HbA1c control
BP control, 80+
Diabetes statin (no CVD)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Brighton and Hove (LAD) | Asset | PCN | Brighton and Hove (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (578 beds) | n/a | Schools (catchment) | 70 | n/a |
| Children's centres | 6 | 14 | Places of worship | 40 | 113 |
| Libraries | 4 | 13 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 18 | 35 | Primary academies | 2 | 7 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma review coverage is 56.0% (England 65.7%; Brighton and Hove 60.1%), falling 2.9% over 2023 to 2025 (England +4.4%), leaving about 1,400 of 3,259 patients unreviewed; COPD reviews reach 68.0% (England 76.4%) across 682 patients. For discussion: run combined asthma and COPD recall with flexible slots and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
High-risk lipid recall and formulary review
Lipid-lowering therapy trails England in CKD (59.1% vs 70.3%), QRISK >= 20% (56.6% vs 63.6%), and CVD diabetes (78.8% vs 84.4%); 56,030 lipid-modifying items cost £2.70 each vs £1.86 in England (£47,065 more). For discussion: deploy pharmacist-led recall for untreated high-risk cohorts alongside a practice formulary review. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
SMI health checks and immunisation recall
Across 588 SMI patients, BP checks reach 72.3% (England 83.4%) and 60.9% at Beaconsfield Medical Practice; 12-month 6-in-1 coverage is 88.0% (England 91.0%) and age-5 MMR2 is 89.6% (5.2 pp below MMR1 at 94.8%). For discussion: combine SMI health checks with targeted recall for overdue 6-in-1 and MMR2 doses. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Working age and frailty access (p2) | Aged 18-64 | Neighbourhood health framework | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure review protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
| Option 2 · High-risk lipid recall and formulary review (p12) | CKD patients treated with lipid lowering therapy · Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | NHS Long Term Plan (diabetes) and National Diabetes Audit | PCN |
| Option 3 · SMI health checks and immunisation recall (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
